Benjamin Burggraaf

Benjamin Burggraaf

Auto-generated profile, based on publicly available information

Benjamin Burggraaf

Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
BBBenjamin Burggraaf
Benjamin Burggraaf
DSDeborah F van Breukelen-Van der Stoep
Deborah F van Breukelen-Van der Stoep
MVMarijke A de Vries
Marijke A de Vries
BKBoudewijn Klop
Boudewijn Klop
ALAnho H Liem
Anho H Liem
MCManuel Castro Cabezas
Manuel Castro Cabezas
Background Patients with rheumatoid arthritis (RA) have an increased risk for cardiovascular disease (CVD). No long-term intervention trials on CVD risk factors have been published, and a debate on the efficacy of controlling traditional risk factors in RA is ongoing. We aimed to evaluate a treat-to-target approach versus usual care regarding traditional CVD risk factors in patients with RA. Methods In this open-label, randomised controlled trial, patients with RA aged <70 years without prior CVD or diabetes mellitus were randomised 1:1 to either a treat-to-target approach or usual care of traditional CVD risk factors. The primary outcome was defined as change in carotid intima media thickness (cIMT) over 5 years, and the secondary outcome was a composite of first occurrence of fatal and non-fatal cardiovascular events. Results A total of 320 patients (mean age 52.4 years; 69.7% female) with RA underwent randomisation and 219 patients (68.4%) completed 5 years of follow-up. The mean cIMT progression was significantly reduced in the treat-to-target group compared with usual care (0.023 [95% CI 0.011 to 0.036] mm vs 0.045 [95% CI 0.030 to 0.059] mm; p=0.028). Cardiovascular events occurred in 2 (1.3%) of the patients in the treat-to-target group vs 7 (4.7%) in those receiving usual care (p=0.048 by log-rank test). Conclusion This study provides evidence on the benefit of a treat-to-target approach of traditional CVD risk factors for primary prevention in patients with well-treated RA. Trial registration number NTR3873.

1 December 2018 in Clinica Chimica Acta
Verified
Journal Article
Closed access
MCManuel Castro Cabezas
Manuel Castro Cabezas
BBBenjamin Burggraaf
Benjamin Burggraaf
BKBoudewijn Klop
Boudewijn Klop

27 May 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
SFSalvador Fernández-Arroyo
Salvador Fernández-Arroyo
AHAnna Hernández-Aguilera
Anna Hernández-Aguilera
MVMarijke A. de Vries
Marijke A. de Vries
BBBenjamin Burggraaf
Benjamin Burggraaf
EZEllen van der Zwan
Ellen van der Zwan
MCManuel Castro Cabezas
Manuel Castro Cabezas
Postprandial lipemia can lead to an accumulation of atherogenic lipoproteins in the circulation associated with systemic low-grade inflammation and an increased risk of cardiovascular disease. Lifestyle and pharmacological treatments are usually prescribed for prevention. Vitamin D3 (cholecalciferol), as an anti-atherogenic agent, is being taken into consideration due to its potential beneficial effects in lipid metabolism and its anti-inflammatory potency. To assess the effects of vitamin D3 in the postprandial lipid profile in obese, vitamin D-deficient women, a non-targeted lipidomics approach using liquid chromatography coupled to a quadrupole time-of flight mass spectrometer was used to identify and quantitate a wide-range of circulating lipid species, including diglycerides, lysophosphatidylcholines, phosphatidylcholines, phosphatidylethanolamines, sphingomyelins and triglycerides. The most important changes were found in plasmatic sphingomyelin levels, which experience a decrease after vitamin D3 intake. Our results suggest a turnover of sphingomyelins, probably due to an increased activity of neutral sphingomyelinases, and, therefore, with implications in the clearance of chylomicrons, LDL and VLDL, decreasing postprandial inflammation and macrophage adherence to endothelia, potentially improving cardiovascular disease risk.

1 April 2018 in Atherosclerosis
Verified
Journal Article
Closed access
BBBenjamin Burggraaf
Benjamin Burggraaf
DSDeborah F. van Breukelen – van der Stoep
Deborah F. van Breukelen – van der Stoep
MVMarijke A. de Vries
Marijke A. de Vries
BKBoudewijn Klop
Boudewijn Klop
JZJende van Zeben
Jende van Zeben
MCManuel Castro Cabezas
Manuel Castro Cabezas

7 January 2020 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
BBBenjamin Burggraaf
Benjamin Burggraaf
NPNadine M.C. Pouw
Nadine M.C. Pouw
SFSalvador Fernández-Arroyo
Salvador Fernández-Arroyo
LZLeonie C. van Vark‐Van der Zee
Leonie C. van Vark‐Van der Zee
GGGert‐Jan M. van de Geijn
Gert‐Jan M. van de Geijn
MCManuel Castro Cabezas
Manuel Castro Cabezas
Aim: Type 2 diabetes mellitus (T2DM) is associated with an increased risk of cardiovascular disease (CVD) linked to atherogenic dyslipidaemia and postprandial hyperlipidaemia. Alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, improves CVD risk by reducing the concentration of low‐density lipoprotein‐cholesterol (LDL‐C). However, effects of PCK9 inhibitors on other aspects of diabetic dyslipidaemia, particularly in the postprandial situation, are less clear. Material and Methods: Twelve male patients with T2DM on an intensive insulin regimen completed a 6‐week randomized, double‐blind, placebo‐controlled, proof‐of‐concept study. Participants received three biweekly dosages of subcutaneous alirocumab (150 mg) or placebo. Before and after the intervention, fasting and postprandial triglyceride (TG) plasma levels, apolipoprotein (apo) B48, lipoprotein composition isolated by ultracentrifugation, vascular function and markers of inflammation were evaluated. Results: Alirocumab treatment reduced fasting plasma TG levels (between group median change −24.7%; P = 0.018) and fasting apoB48 serum levels (−35.9%; P = 0.039) compared with placebo. Alirocumab reduced the plasma TG area under the curve (AUC) (−26.4%; P = 0.006) and apoB48 AUC (−55.7%; P = 0.046), as well as plasma TG incremental AUC (−21.4%; P = 0.04) and apoB48 incremental AUC (−26.8%; P = 0.02). In addition, alirocumab reduced fasting and postprandial TG levels in very low‐density lipoprotein (VLDL) and LDL. Alirocumab improved fasting pulse wave velocity, but no changes in postprandial markers of inflammation were observed. Conclusions: In addition to the well‐known LDL‐C‐reducing effects, 6 weeks of alirocumab treatment lowered both fasting and postprandial plasma TG levels by reducing the TG levels in VLDL and LDL and the concentration of intestinal remnants.

1 July 2017 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
BBBenjamin Burggraaf
Benjamin Burggraaf
MCManuel Castro Cabezas
Manuel Castro Cabezas